KTTA (Pasithea Therapeutics) Tax Provision: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KTTA Pasithea Therapeutics Corp KTTA
29 GF Score
Price $0.45
! 2 Warning Signs
View Full Analysis

What is Pasithea Therapeutics Tax Provision?

Pasithea Therapeutics KTTA -3.89% 29 Tax Provision is $0.00 Mil as of Mar. 2026. GuruFocus rates KTTA with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Pasithea Therapeutics's tax provision for the three months ended in Mar. 2026 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Pasithea Therapeutics Tax Provision Historical Data

* Premium members only.

The historical data trend for Pasithea Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pasithea Therapeutics Tax Provision Chart

Pasithea Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pasithea Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KTTA
29GF Score
Pasithea Therapeutics Corp KTTA
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pasithea Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $0.00 Mil mean?
Pasithea Therapeutics (KTTA) has a Tax Provision of $0.00 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Pasithea Therapeutics and its competitors.
Is Pasithea Therapeutics' Tax Provision too high?
Pasithea Therapeutics' current Tax Provision is $0.00 Mil. Overall, Pasithea Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Pasithea Therapeutics' Tax Provision compare to CELU and GRTX?
Pasithea Therapeutics' Tax Provision of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Pasithea Therapeutics and its competitors. Pasithea Therapeutics's current Tax Provision is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pasithea Therapeutics stock overvalued right now?
Pasithea Therapeutics (KTTA) has a current Tax Provision of $0.00 Mil. The current Tax Provision is $0.00 Mil. Pasithea Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Pasithea Therapeutics (KTTA), the current Tax Provision is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pasithea Therapeutics Business Description

Address 1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
29GF Score

Get the complete analysis for KTTA

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price